
In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed to replace gas and oil tamponades.
Christina Weng, MD, MBA, FASRS, explores the viability of postoperative day 0 exams as a substitute for day 1 after vitreoretinal surgery, revealing promising findings.
How modern tools may lead to customized AMD treatment plans
Published: August 1st 2025 | Updated:
Published: September 8th 2025 | Updated: